Removal of Excess or Unwanted Body Hair
Conditions
Keywords
Hair removal, depilation, epilation
Brief summary
This is a Multi-center, blinded, baseline-controlled, prospective study to evaluate permanent hair reduction and removal for skin types V and VI using IPL.
Detailed description
One hundred and twenty (120) subjects who are Fitzpatrick Skin Type V-VI, and have a suitable treatment area for hair removal will be evaluated in this study. Each subject will receive six treatments at four to six week intervals upon re-growth of hair and return for follow-up visits at one, three and six months after the last treatment. Measurement Equipment Standard High Resolution Digital Camera Labels for hair count Customized hair count sticker templates will be placed directly on the skin and the hairs in this window will be counted at specific visits during the study as detailed in section. Study Procedures Each subject will participate in the study for a period of at least 11 months. The study is anticipated to be completed within twelve months. Test spots Up to 3 test spots will be performed in the selected treatment area to determine the optimal parameters / setting. Treatment The treatment areas are divided into 3 groups. Each Subjects will be allocated to one of the following groups:: * Two small anatomical areas (right and left axillae and double sided bikini line) or; * One double sided large area (right and left thighs) or; * One large area (whole back / abdomen) Based on the mild nature of treatment, anesthesia is not required. Before starting treatment apply a layer of conductive gel to the treatment area. After applying the conductive gel, locate the applicator in close contact, perpendicular to the skin with no pressure applied. Pressing the applicator will fire the IPL pulse. In order to ensure full coverage of the treatment area applicator placement should overlap approximately 1/3 of the previously treated skin. Post-treatment Instructions Cold packs may be placed on the treated area for post treatment cooling. Subjects should be aware that post treatment erythema, edema and some discomfort of the treated areas are possible and should not be a cause for concern. They may also experience some purpura in the treated areas which would be expected to resolve within several days.
Interventions
DEVICETreatment group
The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.
OTHERNo intervention
Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
Sponsors
Venus Concept
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Able to read, understand and provide written Informed Consent; 2. Subject has black or dark brown terminal hairs in the areas to be treated. 3. Terminal hair density requirement of greater than 15 hairs within the hair count site (3x3 cm area) as determined by manual hair count performed by the study investigator. 4. Healthy adult, male or female, 21 years of age or older with skin type V-VI; 5. Having a suitable treatment area for hair removal; 6. Able and willing to comply with the treatment/follow-up schedule and requirements; 7. Women of child-bearing potential (women who have not had a hysterectomy, bilateral oophorectomy or are not postmenopausal) are required to be using a reliable method of birth control at least three months prior to enrollment and throughout the course of the study.
Exclusion criteria
1. Subject has light ,gray terminal or fine hairs in all/some parts of the treated area; 2. Pregnant, expectation of pregnancy, postpartum or nursing (\<6 months); 3. Hormonal disorders that may affect hair growth; 4. Immunosuppressive diseases, including AIDS and HIV infection, or use of immunosuppressive medications; 5. Livedo reticularis; 6. Uncontrolled systemic diseases such as diabetes; 7. Active infections in the treated area; 8. Dysplastic nevi; 9. Significant concurrent skin conditions or any inflammatory skin conditions; 10. Active cold sores, open lacerations or abrasions; 11. Chronic or cutaneous viral, fungal, or bacterial diseases; 12. Current cancer; 13. History of skin cancer or pre-cancerous lesions at the treatment areas; 14. Use of Accutane™ (Isotretinoin) within the past six month; 15. Keloid or Hypertrophic scar formation in the treatment area; 16. Tattoos in the treatment area; 17. Bleeding coagulopathies or use of anticoagulants; 18. Auto-immune disorders; 19. Erythema abigne, when identified treatments should be discontinued; 20. Photosensitivity disorder that can be exacerbated by laser or intense light; 21. Herpes simplex in the treatment area; 22. Use of medications, herbal supplements, perfumes or cosmetics that may affect sensitivity to light; 23. Poor wound healing; 24. Sunburns; 25. Unable or unlikely to refrain from artificial tanning, including the use of tanning booths, prior (at least a month) and during the course of the evaluation; 26. Prior skin treatment with laser or other devices on the same treated areas within the last six months prior to study enrollment or during the course of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hair Count 6 Months Following Last Treatment | 6 months after last treatment | Hair count reduction in marked treatment area assessed from photographs taken 6 months following the last treatment as compared to photographs of the marked treatment area taken at baseline. |
Countries
United States
Participant flow
Recruitment details
The study was terminated and no results analysis was done.
Participants by arm
| Arm | Count |
|---|---|
| Hair Removal With Versa HR 690nm Applicator Subjects with Fitzpatrick skin type V-VI requesting hair removal (right and left axillae and double sided bikini line) or one double sided large area (right and left thighs) or one large area (whole back / abdomen). | 79 |
| Total | 79 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | Lost to Follow-up | 28 |
| Overall Study | Moved away | 4 |
| Overall Study | Physician Decision | 2 |
| Overall Study | Withdrawal by Subject | 6 |
Baseline characteristics
| Characteristic | Hair Removal With Versa HR 690nm Applicator |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 79 Participants |
| Hair count in marked treatment area | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 79 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Sex/Gender, Customized Unknown | 79 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 79 |
| other Total, other adverse events | 0 / 79 |
| serious Total, serious adverse events | 0 / 79 |
Outcome results
Primary
Hair Count 6 Months Following Last Treatment
Hair count reduction in marked treatment area assessed from photographs taken 6 months following the last treatment as compared to photographs of the marked treatment area taken at baseline.
Time frame: 6 months after last treatment
Population: This primary outcome measurement could not be reported as data were not collected.